Almotriptan: A novel 5-HT1B/D agonist for the symptomatic treatment of migraine

Expert Review of Neurotherapeutics

Volumn 1, Issue 1, 2001, Pages 20-27

  Pascual, Julio ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

5 HT1B D agonists; Almotriptan; Migraine; Sumatriptan

Indexed keywords

ALMOTRIPTAN; ANTIMIGRAINE AGENT; ERGOTAMINE; FLUOXETINE; MOCLOBEMIDE; PLACEBO; PROPRANOLOL; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SUMATRIPTAN; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; VERAPAMIL;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; HUMAN; META ANALYSIS; MIGRAINE; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POSTMARKETING SURVEILLANCE; RECURRENCE RISK; REVIEW; SIDE EFFECT; SYMPTOMATOLOGY;

EID: 0035740929     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.1.1.20     Document Type: Review

References (36)

1. Classification of headache disorders, cranial neuralgias and facial pain
2. Burden of migraine in the United Sates: Disability and economic costs
3. Serotonin and migraine
4. Serotonin receptors and the acute attack of migraine
5. Preventive treatment of migraine: An overview
6. Estudio español de calidad de vida en la migraña (II). Patrón de consumo de fármacos y eficacia subjetiva
7. Ergotamine in the acute treatment of migraine. A review and European consensus
8. Sumatriptan. An updated review of its use in migraine
9. Zolmitriptan. A review of its use in migraine
10. Naratriptan: Review
11. Rizatriptan: A new 5-HT1B/1D receptor agonist for the treatment of migraine
12. Eletriptan in acute migraine: A double-blind, placebo-controlled comparison to sumatriptan
13. Pharmacological characterization of almotriptan: An indolic 5-HT receptor agonist for the treatment of migraine
14. Functional profile of almotriptan in animals models predictive of antimigraine activity
15. Absolute bioavailability of oral and sc. almotriptan
16. A clinical trial to determine the lack of food interaction on the bioavailability of almotriptan, a new 5HT1B/1D agonist, in healthy volunteers
17. Pharmacokinetics of oral almotriptan during and outside a migraine attack
18. Pharmacokinetics and tolerability of almotriptan in the elderly
19. The pharmacokinetics and tolerability of almotriptan in renal impairment
20. Effect of MAO-A inhibition on the pharmacokinetics of the novel antimigraine agent, almotriptan, in humans
21. Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers
22. Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan and propranolol in healthy volunteers
23. Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers
24. Therapy with other triptans: Almotriptan
25. Meta-analysis of the efficacy of almotriptan for the treatment of acute migraine attacks
26. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: Results of a large, randomised, double-blind, placebo-controlled study
27. Almotriptan is an effective and well-tolerated treatment for migraine pain: Results of a randomised, double-blind, placebo-controlled clinical trial
28. Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: A double-blind, randomized, parallel-group, optimum-dose comparison
29. Treatment satisfaction, functional status and health-related quality of life of migraine patients treated with almotriptan and sumatriptan
30. Oral almotriptan in the treatment of migraine: Safety and tolerability
31. Hemodynamic and electrocardiographic effects of almotriptan in healthy volunteers
32. Cardiovascular safety profile of almotriptan, a new indolic derivative for the treatment of migraine
33. Long-term efficacy and safety of oral almotriptan: Interim analysis of a 1-year open study
34. The tolerability and efficacy of almotriptan in long-term treatment of migraine
35. Within-patient early vs. delayed treatment of migraine attacks with almotriptan: The sooner the better
36. Practice parameter: Evidence-based guidelines for migraine (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology